PKCzeta as a promising therapeutic target for TNFalpha-induced inflammatory disorders in chronic cutaneous wounds.
MouseWoundBALB/cMalen = 40 male BALB/c mice in total; groups of n=8 (PBS control, T…Local injection into the skin tissue around the wound20 micromolar PKC-zeta inhibitor in 100 microlitres, co-inj…Delayed, late-phase treatment beginning on day 6 after wounding
Model: Full-thickness excisional cutaneous wound (1.0 x 1.0 cm) on the dorsum, with recombinant murine TNF-alpha injected into the peri-wound tissue to model sustained inflammation
Daily peri-wound TNF-alpha from day 6 delayed wound closure and sustained high IL-8, MCP-1, ICAM-1 and MMP9 expression to day 13, whereas co-administration of the PKC-zeta pseudosubstrate inhibitor attenuated the closure delay and markedly suppressed these mediators. In vitro, PKC-zeta inhibition b…
Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.